RVMD
Revolution Medicines, Inc.
Biotechnology · Healthcare · United States
191.31
close · 2026-10-30
value
99
cheaper than peers99
quality
21
stronger fundamentals21
ranked against
Biotechnology (pre-revenue)
value
quality
109 peerswide variation
Value inputs
| measure | company | vs peers |
| cash flow yield, 2 years ago | -0.9% | 98 |
| earnings yield, 2 years ago | -2.0% | 98 |
| cash flow yield, 3 years ago | -0.6% | 97 |
| earnings yield, 3 years ago | -1.6% | 97 |
| cash flow yield, 1 year ago | -1.4% | 96 |
| earnings yield, 1 year ago | -1.9% | 95 |
| earnings yield, latest year | -3.1% | 92 |
| cash flow yield, latest year | -2.2% | 91 |
| price to book | 15.73× | 9 |
9 of 12 measures available
Quality inputs
| measure | company | vs peers |
| operating margin | 0.0% | 50 |
| return on equity | -79.1% | 40 |
| debt to equity | 45.7% | 16 |
3 of 4 measures available
Facts
| market cap | $41B |
| free cash flow | -$711.6M |
| employees | 883 |
| first trade | 2020-02-13 |
| next earnings | 2026-11-04 |
| fundamentals updated | 2026-08-10 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -5.95 | -3.58 | -3.86 | -3.08 |
| free cash flow | -$913.7M | -$567.7M | -$358.3M | -$235.2M |
| net income | -$1.13B | -$600.1M | -$436.4M | -$248.7M |
| revenue | $0 | $0 | $11.6M | $35.4M |
| unusual items | -$15.4M | $4.3M | $115,000 | not reported |